|
|
|
|
|
|
|
Highlights from the 2026 American Urologic Association (AUA) Annual Meeting
|
|
|
|
|
|
|
Retrospective Cohort Analysis of Blue-Light Cystoscopy Using a Claims Database
|
|
Mark Tyson, II, MD, MPH
|
| Mark Tyson reviews a real-world cost analysis of blue-light versus white-light cystoscopy. He draws on a matched Optum database cohort of 794 blue-light and 4,764 white-light patients with a median age of 73. After inverse probability treatment weighting, CIS claims were 18% in the blue-light group versus 9% in the white-light group, and bladder cancer ambulatory visits were 1.3 versus 1.0 per patient per month.
|
|
|
|
|
|
|
|
|
|
| Disitamab Vedotin plus BCG Intravesical Instillation in Patients with HER2 High Expression High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC): Efficacy and Safety Results from the Phase II Formula-01 Trial
|
| Xingliang Tan, MD
|
| Xingliang Tan's Formula-01 phase II trial evaluated disitamab vedotin plus BCG in 78 patients with HER2-high high-risk NMIBC, achieving 1-year disease-free survival of 92.2% versus 73.1% historically with BCG alone in this biomarker-defined subgroup that comprises ~36% of HR-NMIBC cases. The combination was well tolerated with predominantly grade 1-2 adverse events and only 12.8% grade 3-4 events, representing one of the first precision medicine strategies targeting HER2 overexpression to overcome BCG resistance in BCG-naïve high-risk NMIBC.
|
|
|
|
|
|
| First Results from CORE-008 Cohort CX- Phase 2 Study of Intravesical Cretostimogene Grenadenorepvec with Gemcitabine in Patients with High-Risk BCG-Exposed or BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
|
| Trinity Bivalacqua, MD, PhD
|
| Trinity Bivalacqua's AUA 2026 presentation of CORE-008 Cohort CX showed that intravesical cretostimogene plus gemcitabine achieved high-grade event-free survival of 96.0% at 3 months and 89.5% at 6 months in 55 BCG-exposed or BCG-unresponsive NMIBC patients, with complete response rates of 85.7% and 92.3% in CIS-containing disease.
|
|
|
|
|
|
| SUO-CTC: Bladder Trials Update
|
| Siamak Daneshmand, MD
|
| Siamak Daneshmand's AUA 2026 SUO-CTC update reviewed the consortium's expanding bladder cancer trial portfolio, highlighting that SUO-CTC sites drove the majority of enrollment in key trials: PIVOT-006, CORE-008, ADVANCED-2, ABLE-22 , ABLE-32, and LEGEND. Emerging trials include SURF302, TU100P2T5, and RESCUE, demonstrating the consortium's central role in advancing novel intravesical therapies and bladder-sparing strategies for high-risk and BCG-unresponsive NMIBC.
|
|
|
|
|
|
|
|
|
|
|
| A Histopathology-Driven AI Biomarker for Predicting Progression, High-Grade Recurrence, and Early BCG Failure in NMIBC
|
| Kyle Richards, MD, FACS
|
| Kyle Richards' presentation described an AI biomarker from H&E-stained TURBT slides that stratified BCG-treated NMIBC patients by progression risk, high-grade recurrence, and early BCG failure. The multimodal model combining AI score with tumor focality significantly predicted progression-free survival, high-grade disease-free survival, and early BCG failure, with high-risk patients showing worse outcomes, supporting AI-based histopathology for personalized risk stratification beyond standard clinicopathologic factors.
|
|
|
|
|
|
| An Indirect Treatment Comparison of Nogapendekin Alfa Inbakicept-pmln plus Bacillus Calmette–Guérin and TAR-200 in patients with BCG-unresponsive, Non-Muscle Invasive Bladder Cancer CIS ± Papillary
|
| Scott Flanders, PhD
|
| Scott Flanders' AUA 2026 matched-adjusted indirect comparison (MAIC) of nogapendekin alfa inbakicept-pmln plus BCG from QUILT-3.032 versus TAR-200 from SunRISe-1 in BCG-unresponsive NMIBC with CIS ± papillary disease showed numerically similar 12-month complete response rate but significantly fewer treatment-related adverse events with NAI+BCG, representing a 68% reduction in toxicity odds.
|
|
|
|
|
|
| Quality Care Measures Among Patients with High-Risk Non-Muscle Invasive Bladder Cancer with Papillary Carcinoma or CIS Receiving Front-Line BCG or Other Intravesical Therapies
|
| Mukul Singhal, PhD
|
| Mukul Singhal's AUA 2026 SEER-Medicare analysis of 17,495 patients aged ≥65 with high-risk NMIBC revealed substantial gaps in quality-of-care measures: 44% of BCG-treated patients did not initiate therapy within 90 days of diagnosis, 46% failed to receive adequate induction or maintenance BCG, nearly 50% lacked surveillance cystoscopy at recommended 90-120 day intervals, and only 31% underwent repeat TURBT within 6 weeks.
|
|
|
|
|
|
|
|
|
|
|
